Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older

NCT02842866 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

907

Enrollment

INDUSTRY

Sponsor class

Conditions

Meningitis
Meningococcal Meningitis
Meningococcal Infections

Interventions

BIOLOGICAL: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
BIOLOGICAL: Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined

Sponsor

Sanofi Pasteur, a Sanofi Company